Key clinical point: Treatment with stereotactic radiosurgery was superior to non-stereotactic radiotherapy for overall survival in patients with renal cell carcinoma metastatic to the brain.
Major finding: Higher overall survival was observed in the stereotactic radiosurgery cohort both before and following propensity matching. On subset analysis, differences persisted when stratifying for nephrectomy (p<0.001 for all). Treatment at an academic center independently predicted a higher rate of overall survival.
Study details: Data for 2005-2014 in the National Cancer Data Base for metastatic RCC and delivery of intracranial radiotherapy found 2,312 patients, 813 (35%) of whom received SRS and 1,499 of whom received non-SRS radiotherapy. Use of SRS increased from 27% in 2005 to 44% in 2014, and was less often given to low income and uninsured/Medicaid patients (p<0.05).
Disclosures: The researchers had no relevant financial disclosures.
Source: Haque W et al. Clinical Genitourinary Cancer 3 April 2018 https://doi.org/10.1016/j.clgc.2018.03.015
Haque W et al. Clinical Genitourinary Cancer 3 April 2018 https://doi.org/10.1016/j.clgc.2018.03.015
This Week's Must Reads
Must Reads in Renal Cell Carcinoma
First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.
Strong link found between RCC and melanoma, Kim KB et al. Cancer Epidemiol. 2018 Oct 19;57:80-4
Apo B/A1 predicts survival in metastatic renal cell carcinoma, Zhang F et al. Urol Oncol. 2018 Nov 30. doi: 10.1016/j.urolonc.2018.11.010